Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accumulated Expenses (2016 - 2025)

UroGen Pharma's Accumulated Expenses history spans 10 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 27.87% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $13.5 million, up 27.87%, while the annual FY2025 figure was $13.5 million, 27.87% up from the prior year.
  • Accumulated Expenses reached $13.5 million in Q4 2025 per URGN's latest filing, up from $11.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $13.5 million in Q4 2025 to a low of $4.7 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $7.8 million, with a median of $6.9 million recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 1905.11% in 2021 against a maximum downside of 27.28% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $6.9 million in 2021, then increased by 18.84% to $8.3 million in 2022, then soared by 30.97% to $10.8 million in 2023, then fell by 2.26% to $10.6 million in 2024, then grew by 27.87% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Accumulated Expenses are $13.5 million (Q4 2025), $11.1 million (Q3 2025), and $11.6 million (Q2 2025).